About Us
Our Company
Leadership
Compliance
Contact
Medical Education Grants
Our
Medicines
YCANTH
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline VP-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
Menu
About Us
Our Company
Leadership
Compliance
Contact
Medical Education Grants
Our
Medicines
YCANTH
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline VP-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
For information about YCANTH™ or to request a representative, visit YCANTHPro.com
Press Releases
Press Releases
Year
2018
2019
2020
2021
2022
2023
2024
Submit
March 26, 2024
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
February 29, 2024
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
February 29, 2024
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
February 27, 2024
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
February 22, 2024
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2023 Financial Results on February 29 2024
< previous
1
2
3
4
5
6
next >
